Shots: SunPharma to receive upfront and milestones for licensing its product to Hikma and will supply Ilumya. Hikma will be responsible for the registration and commercialization of the product in […]readmore
Tags : tildrakizumab
Shots: Sun Pharma has filed manufacturing and marketing authorization of Tildrakizumab to the PMDA for moderate-to-severe psoriasis and psoriatic arthritis in Japan Additionally, Sun Pharma has acquired Pola Pharma and […]readmore
Shots: NICE has recommended Ilumetri (tildrakizumab) as a cost-effective option for the treatment of adults patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy following its assessment submission […]readmore
Regulatory
Almirall’s Ilumetri (tildrakizumab) Receives NICE’s Provisional Approval for Moderate-To-Severe Plaque
Shots: The approval is based on P-III reSURFACE 1 & reSURFACE 2 studies assessing Ilumetri (tildrakizumab) in 1,800 patients with moderate-to-severe plaque psoriasis across 200 sites WW reSURFACE 1 & […]readmore